• Publications
  • Influence
Pharmacokinetics and drug metabolism in the elderly
  • U. Klotz
  • Medicine
  • Drug metabolism reviews
  • 1 May 2009
In the elderly, hepatic drug clearance of some drugs can be reduced and CYP-mediated phase I reactions are more likely to be impaired than phase II metabolism, which is relatively preserved in the elderly. Expand
Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4
It is shown that piperine inhibits both the drug transporter P-glycoprotein and the major drug-metabolizing enzyme CYP3A4. Expand
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
  • S. Shi, U. Klotz
  • Medicine
  • European Journal of Clinical Pharmacology
  • 5 August 2008
This update of pharmacokinetic, pharmacodynamic, and clinical data will provide the necessary guide by which to select between the various PPIs that differ—based on pharmacodynamic assessments—in their relative potencies. Expand
The clinical impact of pharmacogenetics on the treatment of epilepsy
This article reviews the published work with particular emphasis on pharmacogenetic alterations that may affect efficacy, tolerability, and safety of antiepileptic drugs (AEDs), including variation in genes encoding drug target, drug transport, drug metabolizing, and human leucocyte antigen (HLA) proteins. Expand
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
Evidence is provided that proton pump inhibitors are substrates and inhibitors of P-glycoprotein, which might explain some of the drug interactions with proton Pump Inhibitors observed in vivo. Expand
The clinical implications of ageing for rational drug therapy
Present knowledge of age-related problems in drug action and their clinical implications for an increasingly important population of elderly patients are summarized. Expand
CYP2C19 polymorphism and proton pump inhibitors.
Limited data suggest that proton pump inhibitors-induced healing rates in gastro-oesophageal reflux disease are apparently higher in poor metabolizers/het extensive metabolizers than in extensive metabolites of CYP2C19, and initial genotyping for this enzyme and higher dosage in extensive metabolizer is likely to improve the clinical efficacy of proton pumps. Expand
Clinical Pharmacokinetics and Use of Infliximab
Following single and multiple infusions of infliximab, no relevant differences in median concentration-time profiles have been observed between patients with Crohn’s disease, patients with rheumatoid arthritis and patients with psoriasis. Expand
Drug Interactions with Herbal Medicines
The present article summarizes herbal medicine-drug interactions involving mainly inhibition or induction of cytochrome P450 enzymes and/or drug transporters and describes the clinical implications of these interactions. Expand
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.
A considerably higher extraction ratio than the unbound fraction of diazepam exists in these animal species, and blood clearance exceeds liver blood flow, giving reason to assume a much higher ability of the liver to metabolize D, and a species-dependent extrahepatic metabolism. Expand